© 1997 American Heart Association, Inc.
Articles |
Genetic Factors Precipitating Type III Hyperlipoproteinemia in Hypolipidemic Transgenic Mice Expressing Human Apolipoprotein E2
From the Gladstone Institute of Cardiovascular Disease (Y.H., S.C.R., R.W.M.), the Cardiovascular Research Institute (Y.H., R.W.M.), and the Departments of Pathology and Medicine (R.W.M.), University of California, San Francisco.
Correspondence to Robert W. Mahley, MD, PhD, Gladstone Institute of Cardiovascular Disease, PO Box 419100, San Francisco, CA 94141-9100.
Abstract Several factors are hypothesized to precipitate or exacerbate type III hyperlipoproteinemia (HLP) in humans. Among such factors are those that directly overload remnant lipoprotein production or disrupt removal pathways, including an increased ratio of apolipoprotein (apo) E2 to normal apoE, overproduction of apoB-containing lipoproteins, and decreased LDL receptor activity. Hypolipidemic apoE2-transgenic mice bred onto an apoE-null background had dramatically higher plasma total cholesterol (192±26 mg/dL for males, 203±40 mg/dL for females) and triglyceride (295±51 mg/dL for males, 277±58 mg/dL for females) levels than apoE2 mice with endogenous mouse apoE. Thus, eliminating normal apoE in the presence of apoE2 (thereby increasing the relative abundance of the defective ligand) can convert a hypolipidemic to a hyperlipidemic phenotype. Hypolipidemic apoE2 transgenic mice overexpressing human apoB had moderate remnant accumulation compared with apoE2-only or apoB-only transgenic mice, indicating that overproduction of apoB-containing lipoproteins in the presence of apoE2 can augment remnant production. Hypolipidemic apoE2 transgenic mice bred onto an LDL receptor–null background had markedly higher plasma total cholesterol (288±51 mg/dL for males, 298±73 mg/dL for females) and triglyceride (356±72 mg/dL for males, 317±88 mg/dL for females) levels than apoE2-only mice, and remnant accumulation increased even in apoE2 mice with a heterozygous LDL receptor–knockout background (compared with apoE2-only mice), suggesting that reducing or eliminating a major receptor-mediated remnant-removal pathway in the presence of apoE2 can also precipitate a hyperlipidemic phenotype. In all cases where either lipoprotein remnant production or removal pathways were severely stressed, increased remnant accumulation was apparent. As judged by the chemical characteristics of the remnant lipoproteins, the lipoprotein phenotype was quite similar to that of human type III HLP, especially in the apoE2-expressing mice with no endogenous apoE or LDL receptors, and thus these mice represent improved models of the disorder.
Key Words: type III hyperlipoproteinemia • LDL receptor • apolipoprotein B • apolipoprotein E • transgenic mice
This article has been cited by other articles:
 |
|
 |
|
  K. M. Mann, F. E. Thorngate, Y. Katoh-Fukui, H. Hamanaka, D. L. Williams, S. Fujita, and B. T. Lamb Independent effects of APOE on cholesterol metabolism and brain A{beta} levels in an Alzheimer disease mouse model Hum. Mol. Genet., September 1, 2004; 13(17): 1959 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Athanasopoulos, J. S. Owen, D. Hassall, M. G. Dunckley, J. Drew, J. Goodman, A. D. Tagalakis, D. R. Riddell, and G. Dickson Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice Hum. Mol. Genet., October 1, 2000; 9(17): 2545 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsukamoto, C. Maugeais, J. M. Glick, and D. J. Rader Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice J. Lipid Res., February 1, 2000; 41(2): 253 - 259. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. W. van Dijk, B. J.M. van Vlijmen, M. P.J. de Winther, B. van ’t Hof, A. van der Zee, H. van der Boom, L. M. Havekes, and M. H. Hofker Hyperlipidemia of ApoE2(Arg158-Cys) and ApoE3-Leiden Transgenic Mice Is Modulated Predominantly by LDL Receptor Expression Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2945 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, Z.-S. Ji, W. J. Brecht, S. C. Rall Jr, J. M. Taylor, and R. W. Mahley Overexpression of Apolipoprotein E3 in Transgenic Rabbits Causes Combined Hyperlipidemia by Stimulating Hepatic VLDL Production and Impairing VLDL Lipolysis Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2952 - 2959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Mahley, Y. Huang, and S. C. Rall , Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J. Lipid Res., November 1, 1999; 40(11): 1933 - 1949. [Abstract] [Full Text]
|
|
|
|
|
|
K. W. van Dijk, B. J. M. van Vlijmen, H. B. van't Hof, A. van der Zee, S. Santamarina-Fojo, T. J.C. van Berkel, L. M. Havekes, and M. H. Hofker In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE J. Lipid Res., February 1, 1999; 40(2): 336 - 344. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Mahley and Z.-S. Ji Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E J. Lipid Res., January 1, 1999; 40(1): 1 - 16. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Huang, X. Q. Liu, S. C. Rall Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia J. Biol. Chem., October 9, 1998; 273(41): 26388 - 26393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, X. Q. Liu, S. C. Rall Jr., and R. W. Mahley Apolipoprotein E2 Reduces the Low Density Lipoprotein Level in Transgenic Mice by Impairing Lipoprotein Lipase-mediated Lipolysis of Triglyceride-rich Lipoproteins J. Biol. Chem., July 10, 1998; 273(28): 17483 - 17490. [Abstract] [Full Text] [PDF]
|
|